JNJ Archives - Medical Design Sourcing

Johnson & Johnson (NYSE:JNJ) has agreed to pay $99 million to put opioid-related claims in the State of West Virginia to bed.

The state has removed J&J from an ongoing trial in Kanawha County.

West Virginia will use the funds to support community efforts targeting the opioid crisis.

The settlement did not include an admission of liability or wrongdoing.

The settlement related to former sales of the drugs Duragesic (fentanyl transdermal system), Nucynta (tapentadol) and Nucynta ER, which

West Virginia had accused Janssen, Teva and Allergan of violating state laws related to shipping opioids.

In January, J&J announced similar deals with Colorado and Nevada.

In 2015, Johnson & Johnson divested U.S. license rights for Nucynta-based products.

The company permanently discontinued sales of Duragesic transdermal systems in 2020.

JNJ shares were up 0.16% to $180.22 in morning trading.

Photo by Miguel Á. Padriñán from Pexels

The market for injectable anti-HIV therapeutics will be worth $28 billion by 2029, according to projections from the analyst and consulting firm GlobalData.

GlobalData valued the broader HIV therapeutics market at $22.9 billion in 2019 across the U.S., France, Germany, Italy, Spain, U.K. and Japan.

While the overall market is growing at a low single-digit rate, injectable therapies will likely see more brisk growth, GlobalData projects.

To date, the majority of HIV therapies are orally-delivered antiretroviral drugs although a handful of injectable drugs have hit been introduced over the years.

Future injectable anti-HIV therapies could be administered less frequently than oral drugs.

One early injectable anti-HIV therapy, Fuzeon (enfuvirtide) from Roche (OTCMKTS:RHHBY), is administered multiple times per day, posing a challenge for adh…

JNJ

Johnson & Johnson announces opioid settlement with West Virginia

Injectable anti-HIV therapies could see strong growth